The Uterine Fibroid Embolization Device Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Uterine Fibroid Embolization Device Market:
https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report
According to The Business Research Company’s Uterine Fibroid Embolization Device Global Market Report 2024, The uterine fibroid embolization device market size has grown strongly in recent years. It will grow from $5.3 billion in 2023 to $5.62 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing incidence of uterine fibroids, preference for non-surgical alternatives, awareness and education initiatives, focus on women’s health, shift towards outpatient procedures, physician training programs..
The uterine fibroid embolization device market size is expected to see steady growth in the next few years. It will grow to $6.75 billion in 2028 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing awareness of non-invasive treatments, global expansion of healthcare services, rise in female healthcare initiatives, integration with multidisciplinary care, expansion of outpatient services.. Major trends in the forecast period include increasing adoption of minimally invasive procedures, advancements in embolic agents, personalized treatment approaches, focus on outpatient ufe procedures, integration of imaging technologies, research on bioresorbable embolic agents..
The growing demand for minimally invasive surgeries is expected to propel the growth of the uterine fibroid embolization device market going forward. Minimally invasive surgeries refer to surgical approaches that use small incisions or natural body openings to access and treat internal structures, organs, or tissues to minimize trauma to the patient’s body. Uterine fibroid embolization devices are essential tools that enable minimally invasive surgeries to treat uterine fibroids effectively. These specialized devices are meticulously designed to minimize invasiveness by using small incisions, reducing the impact on surrounding tissues. They cater to the increasing demand for less invasive medical procedures, ultimately improving patient outcomes. For instance, in January 2023, according to Intuitive Surgical Inc., a US-based technology corporation specializing in minimally invasive care products, in 2022, approximately 1,875,000 surgical procedures were performed with vinci surgical systems, an increase of approximately 18% compared with approximately 1,594,000 surgical procedures performed in 2021. Therefore, the growing demand for minimally invasive surgeries drives the growth of the uterine fibroid embolization device market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp
The uterine fibroid embolization device market covered in this report is segmented –
1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques
2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment
3) By End User: Hospitals, Clinics, Ambulatory Surgical Center
Major companies operating in the uterine fibroid embolization device market are developing innovative products such as the TruClear system to address the growing need for minimally invasive treatments for uterine fibroids and improve the safety and efficacy of treatment for uterine fibroids. The TruClear system is a mechanical hysteroscopic tissue removal system that is used to treat intrauterine abnormalities (IUA). It is a flexible catheter that is inserted into the uterus through the cervix. For instance, in November 2022, Medtronic Private Limited, an India-based industrial medical equipment manufacturer, launched the new TruClear system. This mechanical hysteroscopic tissue removal system treats intrauterine abnormalities (IUA). It is a safe and effective option for the treatment of IUA. Additionally, it is a compact, flexible catheter with a spinning nitinol wire loop, continuous inflow and outflow, integrated suction, and high-definition imaging, which contributes to improving the precision and safety of uterine fibroid treatment methods.
The uterine fibroid embolization device market report table of contents includes:
- Executive Summary
- Uterine Fibroid Embolization Device Market Characteristics
- Uterine Fibroid Embolization Device Market Trends And Strategies
- Uterine Fibroid Embolization Device Market – Macro Economic Scenario
- Global Uterine Fibroid Embolization Device Market Size and Growth
.
.
.
- Global Uterine Fibroid Embolization Device Market Competitive Benchmarking
- Global Uterine Fibroid Embolization Device Market Competitive Dashboard
- Key Mergers And Acquisitions In Uterine Fibroid Embolization Device Market
- Uterine Fibroid Embolization Device Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- Johnson and Johnson Pvt Ltd.
- Abbott Laboratories
- Medtronic plc.
- Siemens Healthineers Ltd.
- Koninklijke Philips N.V.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
